Larka is pleased to announce that it performed the Commercial Due-Diligence for Clean Biologics group – backed by Archimed -, on their acquisition of Biodextris.
As a result of the M&A process, Clean Biologics, a group providing services for the BioPharma industry, has acquired Biodextris, a Biologics Contract Development and Manufacturing Organization - CDMO - based in Laval – Montreal –, Quebec. Biodextris provides analytical and process development, early-clinical phase manufacturing and quality control testing services for clients in the vaccine and biologics industries.
This acquisition enables Clean Biologics to expand its activities by including Biodextris’ complementary services, but also provides an opportunity to establish its presence on the North American market, with the objective to expand its activities in this region.
Joe Zimmermann, president and CEO, Biodextris, highlighted that this acquisition will “position Biodextris for near-term expansion”. He also added: “we are excited to join forces with the Clean Biologics group and in the near future we look forward to introducing our shared client base to the advantages of this alliance.”
What's Next for Biodextris?
As a new entity within the Cleans Biologics group, which includes Clean Cells - previously acquired by Archimed during an M&A process also supported by Larka in 2018 – Biodextris will continue to expand its service portfolio, which currently includes analytical and process development, early-phase clinical manufacturing and quality control testing services for clients in the vaccine and biologics industries.
Joseph Jammal, president and CEO, Clean Biologics, confirmed that having Biodextris joining the group will “allow to provide broader services” to their customers, adding that “the cultures of the three companies in the group - Clean Cells, Naobios and now Biodextris - are very similar in terms of customer focus and personalization, making this acquisition a natural fit for the very promising expansion projects to come.”
How Did Larka Support this M&A Process?
In order to advise Archimed and Clean Biologics on Biodextris’ growth potential and value-creating opportunities, Larka’s M&A team has performed a comprehensive Commercial Due-Diligence. As a leading CDD advisor to Private Equity firms within the BioPharma industry, Larka has leveraged its advanced analytics and extensive proprietary benchmarks to assess synergy value, growth potential and identify value-creating opportunities.
A Contract Development and Manufacturing Organization - CDMO - created in 2015 and based in Laval -Montreal - Canada, Biodextris provides analytical and process development, early-phase clinical manufacturing and quality control testing services for clients in the vaccine and biologics industries.
The Biodextris team has decades of expertise working in mid- and large-sized vaccine companies. It develops, manufactures and tests a wide range of biologic products for vaccine, pharmaceutical and other applications. It has worked on numerous products at all phases of clinical development for programs conducted in the US, Canada and Europe.
For more information, please visit www.biodextris.com
About Clean Biologics
The Clean Biologics group provides services to the biopharmaceutical industry. These include quality control and manufacturing of biological starting materials, such as cell banks and virus seed stocks, and clinical batches of biological drugs through its two subsidiaries: Clean Cells and Naobios – both of which offer complementary activities. The group specializes in biological and viral safety of biopharmaceutical products, such as recombinant proteins, therapeutic antibodies, viral vaccines, phage therapy, and cell and gene therapy products.
For more information, please visit www.clean-biologics.com
About Clean Cells
Founded in 2000, Clean Cells offers (i) quality control and biological safety tests for biopharmaceutical products to assist in regulatory compliance, (ii) production of cell banks and GMP-grade BSL2/BSL3 virus seed stock, (iii) supply of secure cold storage for these products, alongside development and validation of bespoke analysis tools and (iv) production of bacteriophages for phage therapy.
For more information, please visit www.clean-cells.com
Clean Biologics acquired Naobios in 2019, a CDMO (Contract Development and Manufacturing Organization) providing bioprocess development and GMP production for clinical batches of viral vaccines BSL2/BSL3, oncolytic viruses and viral vectors.
For more information, please visit www.naobios.com
Larka is a management consulting firm, exclusively dedicated to the Biotech and Pharma industry. We assist all players that are somehow involved technically, commercially or financially into drug discovery, development and manufacturing, such as Biotech & Pharma companies, Contract Services Organizations, Equipment or Raw Materials Suppliers, Private Equity firms or Investment Banks.
Covering Technical, Operational, Commercial and Strategic activities, Larka has developed a unique combination of expertise – including TechOps, CMC & Outsourcing, Operational & Commercial excellence, Marketing & Sales, Corporate Strategy and M&A - giving Larka’s clients a full appreciation of their capabilities and a 360° view, full-potential vision, on the industry’s opportunities, synergies and risks.
For more information, please visit www.larka.com